On Thursday, Xilinx, Inc. (NASDAQ:XLNX)’s shares declined -1.27% to $41.86.
Xilinx, Inc. (XLNX) declared first customer shipment of the industry’s first 16nm multiprocessor SoC (MPSoC) a quarter ahead of plan. The early release of the Zynq® UltraScale+™ MPSoC enables Xilinx customers to start designing and delivering MPSoC-based systems recently. Built using TSMC’s 16FF+ process, the Zynq® UltraScale+™ MPSoC enables the development of next-generation embedded vision, ADAS, I-IoT and communications systems by providing 5X system-level performance/watt and any-to-any connectivity with the security and safety required for next-generation systems.
Xilinx, Inc. designs and develops programmable devices and associated technologies worldwide. Its programmable devices comprise integrated circuits (ICs) in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; software design tools to program the PLDs; targeted reference designs; printed circuit boards; and intellectual property (IP), which comprises of Xilinx and various third-party verification and IP cores.
Theravance Inc (NASDAQ:THRX)’s shares gained 5.43% to $7.57.
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) declared data presented by GSK at the European Respiratory Society (ERS) International Congress (poster PA1001), from an exploratory post-hoc analysis of phase III data, which showed that patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who received Anoro® Ellipta® (UMEC/VI 62.5/25mcg) had a reduced risk of experiencing a clinically important deterioration contrast to tiotropium 18mcg or placebo over a 12-week treatment period.
This post-hoc analysis used a novel, composite endpoint, defined as a clinically important deterioration, to assess the effect of treatment on a number of factors that are each believed to represent a worsening of a patient’s COPD. The analysis examined the time to a first clinically important deterioration which was determined by the occurrence of any of the following events: A decrease in lung function of ≥100 ml from baseline as measured by trough FEV1; a deterioration in health-related quality of life defined as ≥4 unit enhance from baseline in St George’s Respiratory Questionnaire (SGRQ) total score; or the occurrence of an on-treatment moderate-to-severe COPD exacerbation.
The results of the analysis showed that the risk of experiencing a clinically important deterioration was significantly lower for patients on UMEC/VI 62.5/25mcg once daily contrast to tiotropium 18mcg once daily (hazard ratio: 0.62; 95% confidence interval [CI]: 0.54, 0.71; p < 0.001) or placebo (hazard ratio: 0.37; 95% CI: 0.30, 0.45; p < 0.001) in an intention to treat population, based on analysis of time to first deterioration.
Theravance, Inc., a royalty administration company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist partnershipagreement and the planned alliance agreement with Glaxo Group Limited (GSK).
At the end of Thursday’s trade, Liberty Global plc - Class A Ordinary Shares (NASDAQ:LBTYA)‘s shares surged 2.36% to $43.96.
Liberty Global plc (“Liberty Global”) (NASDAQ: LBTYA, LBTYB, LBTYK, LILA and LILAK) recently declared its inclusion in the Dow Jones Sustainability World and North America Indices.
The Dow Jones Sustainability Indices track the performance of leading companies in terms of their economic, environmental, governance and social performance. Each year, over 3,000 publicly traded companies are invited to take part in this corporate sustainability assessment and Liberty Global’s inclusion is evidence of the company’s continued progress in delivering its Corporate Responsibility strategy.
ighlights from Liberty Global’s Corporate Responsibility program in 2014 comprised of:
- Empowering young people to acquire and grow their digital skills through programs such as CoderDojo and YouRock. Liberty Global became a partner of both programs, which are part of its ‘promoting a digital society’ strategy and demonstrates its commitment to the European Commission’s Grand Coalition for Digital Jobs;
- Engaging with thousands of entrepreneurs across a number of markets in online competitions and initiatives to support innovation in digital society. Projects comprised of Pitch to Rich in the U.K., Telenet’s Kickstart accelerator in Belgium, and Think Big in Poland;
- Ongoing to make advances in conserving energy and reducing greenhouse gas emissions relative to the company’s key measure - the amount of data traffic consumed by our customers. In 2014, the company improved its energy efficiency by 34% and its carbon efficiency by 31%;
- Refurbishing 4.4 million set-top boxes and modems, avoiding about 7,200 metric tons of waste that would otherwise have ended up in landfill sites. This also resulted in a financial saving of $320 million;
Liberty Global plc, together with its auxiliaries, provides video, broadband Internet, fixed-line telephony, and mobile services in Europe, Chile, Puerto Rico, and internationally. The company offers various residential services, counting video services comprising basic and premium programming, which can be viewed on the television and Internet connected devices; electronic programming guide, high definition (HD) channels, digital video recorder (DVR), and HD DVR services; video-on-demand, set-top boxes, pay-per-view programming, and programming in three-dimensional format services, in addition to television applications that allow access to programming on laptops, smartphones, and tablets; and entertainment, sports, movies, documentaries, lifestyles, news, adult, children, and ethnic and foreign channels.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), ended its Thursday’s trading session with -2.46% loss, and closed at $6.74.
Achillion Pharmaceuticals, Inc. (ACHN) declared additional interim results from a Phase 2 study evaluating odalasvir (also known as ACH-3102), a NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for either six or eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection. Of the patients treated for six weeks in this cross-over cohort, 100 percent (n=6/6) remained HCV RNA undetectable twelve weeks after concluding therapy (SVR12). Formerly, Achillion stated results from this study counting 100 percent SVR24 for the initial cohorts counting 12 patients treated for eight weeks and 100 percent SVR24 for 12 patients treated for six weeks.
In May 2015, Achillion declared it had granted Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion’s HCV assets which comprise odalasvir, ACH-3422, and sovaprevir.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
